Skip to main content

and
  1. No Access

    Article

    Multiplexed, single-molecule, epigenetic analysis of plasma-isolated nucleosomes for cancer diagnostics

    The analysis of cell-free DNA (cfDNA) in plasma provides information on pathological processes in the body. Blood cfDNA is in the form of nucleosomes, which maintain their tissue- and cancer-specific epigeneti...

    Vadim Fedyuk, Nir Erez, Noa Furth, Olga Beresh in Nature Biotechnology (2023)

  2. Article

    Author Correction: ChIP-seq of plasma cell-free nucleosomes identifies gene expression programs of the cells of origin

    A Correction to this paper has been published: https://doi.org/10.1038/s41587-021-00831-9.

    Ronen Sadeh, Israa Sharkia, Gavriel Fialkoff, Ayelet Rahat in Nature Biotechnology (2021)

  3. Article

    Author Correction: ChIP-seq of plasma cell-free nucleosomes identifies gene expression programs of the cells of origin

    A Correction to this paper has been published: https://doi.org/10.1038/s41587-021-00853-3.

    Ronen Sadeh, Israa Sharkia, Gavriel Fialkoff, Ayelet Rahat in Nature Biotechnology (2021)

  4. No Access

    Article

    ChIP-seq of plasma cell-free nucleosomes identifies gene expression programs of the cells of origin

    Cell-free DNA (cfDNA) in human plasma provides access to molecular information about the pathological processes in the organs or tumors from which it originates. These DNA fragments are derived from fragmented...

    Ronen Sadeh, Israa Sharkia, Gavriel Fialkoff, Ayelet Rahat in Nature Biotechnology (2021)

  5. No Access

    Article

    Recurrent TP53 missense mutation in cancer patients of Arab descent

    Hereditary cancer comprises more than 10% of all breast cancer cases. Identification of germinal mutations enables the initiation of a preventive program that can include early detection or preventive treatmen...

    Aviad Zick, Luna Kadouri, Sherri Cohen, Michael Frohlinger in Familial Cancer (2017)

  6. No Access

    Article

    An observational cohort study of bevacizumab and chemotherapy in metastatic colorectal cancer patients: safety and efficacy with analysis by age group

    Bevacizumab improves survival when added to chemotherapy in metastatic colorectal cancer (mCRC). We assessed the safety and efficacy of bevacizumab in mCRC patients ≥70 years old (YO) vs. those <70 YO. mCRC pa...

    Esther Tahover, Ayala Hubert, Mark Temper, Azzam Salah, Tamar Peretz in Targeted Oncology (2015)

  7. No Access

    Article

    Hypertension as a predictive biomarker in bevacizumab treatment for colorectal cancer patients

    Bevacizumab treatment is associated with an increased risk of hypertension (HTN), a potential marker for effectiveness. We aimed to assess whether grades 2–3 HTN during bevacizumab treatment was associated wit...

    Esther Tahover, Beatrice Uziely, Azzam Salah, Mark Temper, Tamar Peretz in Medical Oncology (2012)